AstraZeneca Buys Omniose to Expand Vaccine Pipeline
The acquisition folds the early-stage bacterial vaccine developer into AstraZeneca's infectious diseases division after a three-year research collaboration.
Updated on Nov. 10, 2026 in Biotech
AstraZeneca has acquired Omniose, a US-based early-stage biotechnology firm developing bacterial infection vaccines, and folded its business into the company's infectious diseases division. Financial terms of the deal were not disclosed.
Why it matters
The move brings a proprietary bacterial vaccine platform into a major drugmaker's portfolio at a time when AstraZeneca has been scaling back some vaccine programs. It shows how drugmakers are tying acquisitions to existing research partnerships in infectious disease.
Omniose's proprietary platform engineers and assembles bacterial vaccine components in a single process, according to the company's description. The deal's price and the platform's clinical development timeline were not disclosed.
The players
AstraZeneca
A multinational pharmaceutical company headquartered in Cambridge, UK, with a broad pipeline across oncology, cardiovascular, and infectious disease therapies.
Omniose
A US-based early-stage biotechnology company developing bacterial infection vaccines using a proprietary engineering platform.
The details
AstraZeneca acquired Omniose, which uses a single-process platform to engineer and assemble bacterial vaccine components, and integrated the business into its infectious diseases division. The acquisition followed a three-year exclusive research collaboration between the two companies, and Omniose announced the deal on Tuesday.
Timeline
Three years before the acquisition: exclusive research collaboration between AstraZeneca and Omniose began.
2024: AstraZeneca discontinued its Covid-19 vaccine.
November 10, 2026: AstraZeneca's acquisition of Omniose was announced.
The Tech Race
AstraZeneca discontinued its Covid-19 vaccine in 2024 and now offers Beyfortus for respiratory syncytial virus and FluMist for influenza. Buying Omniose signals a move back into vaccine development through bacterial targets as the company explores cancer vaccines.
For patients, the deal does not change available products today, since Omniose has no approved vaccines listed in the source. Any future bacterial vaccine developed on this platform would still need clinical trials and regulatory approval before reaching patients.
The takeaway
Drugmakers are increasingly pairing long-running research collaborations with full acquisitions, which can reduce risk for both sides. Readers tracking vaccine development should watch whether AstraZeneca discloses which Omniose candidates it plans to advance.
Further reading
For more on the science behind these programs, explore the Biotech section.
